Cardano Risk Management B.V. Boosts Stake in AbbVie Inc. $ABBV

Cardano Risk Management B.V. grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 536,670 shares of the company’s stock after purchasing an additional 12,629 shares during the period. AbbVie makes up about 1.3% of Cardano Risk Management B.V.’s holdings, making the stock its 20th largest holding. Cardano Risk Management B.V.’s holdings in AbbVie were worth $124,260,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter worth approximately $26,000. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the 2nd quarter valued at $36,000. Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth $39,000. Finally, Access Investment Management LLC purchased a new stake in shares of AbbVie during the 2nd quarter worth $44,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on ABBV. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Citigroup dropped their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, Raymond James Financial set a $256.00 price objective on shares of AbbVie in a report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Stock Up 1.8%

Shares of AbbVie stock opened at $231.57 on Tuesday. The firm has a market cap of $409.28 billion, a price-to-earnings ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company’s 50-day simple moving average is $223.73 and its 200-day simple moving average is $221.37.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.